Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations
(MedPage Today) -- Osimertinib (Tagrisso) demonstrated promising clinical activity as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) with uncommon EGFR mutations, the nonrandomized UNICORN trial from Japan...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | Japan Health | Lung Cancer | Non-Small Cell Lung Cancer